Monte Rosa Therapeutics, Inc. Income Statement

Income Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 75.62M
Gross Profit 75.62M
Operating items
Research & Development 24.00M57.16M85.06M111.27M121.56M
Selling, General & Administrative 4.00M15.73M27.32M32.04M35.17M
Restructuring Costs 27.30M29.63M
Other Operating Expenses 0.11M0.02M-29.63M
Operating Expenses 28.01M72.88M112.38M143.31M156.73M
Operating Income -28.01M-72.88M-112.38M-143.31M-81.11M
EBIT -28.01M-72.88M-112.38M-143.31M-81.11M
Non-operating items
Non Operating Investment Income -0.13M
Interest & Investment Income 0.01M0.05M3.76M9.33M10.57M
Other Non Operating Income -0.20M-0.16M0.01M-0.93M0.42M
Non Operating Income -7.87M-1.08M3.88M8.30M10.98M
Net income details
EBT -25.77M-64.07M-108.50M-135.01M-70.13M
Tax Provisions 0.34M2.60M
Profit After Tax -35.90M-74.00M-108.50M-135.40M-72.70M
Income from Continuing Operations -25.77M-64.07M-108.50M-135.35M-72.73M
Consolidated Net Income -25.77M-64.07M-108.50M-135.35M-72.73M
Income towards Parent Company -25.77M-64.07M-108.50M-135.35M-72.73M
Net Income towards Common Stockholders -25.77M-64.07M-108.50M-135.35M-72.73M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 42.54M46.51M48.40M50.08M61.44M
Shares Outstanding (Diluted Average) 51.40M73.91M
EBITDA -36.94M-74.92M-108.23M-136.32M-73.33M